Avrobio Inc traded at $0.97 this Thursday August 4th, increasing $0.001 or 0.06 percent since the previous trading session. Looking back, over the last four weeks, Avrobio Inc gained 2.92 percent. Over the last 12 months, its price fell by 87.62 percent. Looking ahead, we forecast Avrobio Inc to be priced at 0.89 by the end of this quarter and at 0.81 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Takeda 3,734.00 16.00 0.43% 2.92%
Applied Genetic Technologies 0.39 0.005 1.24% -89.42%
Akebia Therapeutics 0.41 0.02 4.99% -85.71%
Alnylam Pharmaceuticals 224.05 12.04 5.68% 15.55%
Bluebird Bio 4.58 0.36 8.53% -82.30%
Epizyme 1.48 -0.01 -0.67% -77.54%
Gilead Sciences 61.91 -0.36 -0.58% -10.66%
Intercept Pharmaceuticals 15.65 1.81 13.08% -7.23%
Ionis Pharmaceuticals 43.29 2.27 5.53% 9.93%
Karyopharm Therapeutics 4.53 0.03 0.67% -23.61%
MacroGenics 3.94 0.19 5.07% -84.57%
Pfizer 49.86 0 0% 10.65%
Roche Holding 318.45 1.70 0.54% -9.85%
Sanofi 96.81 0.48 0.50% 12.24%
Sangamo BioSciences 4.77 -0.03 -0.63% -52.16%
Sarepta Therapeutics 101.45 5.34 5.56% 29.17%

Avrobio Inc
AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with a lentiviral vector to insert a functional copy of the gene that is defective in the target disease. The Company is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of six lentiviral-based gene therapy programs, which includes AVR-RD-01 for the treatment of Fabry disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-06 for the treatment of Gaucher disease type 3; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.